trimix

11/28/2014 - "Especially in a therapeutic setting, sonoporation with TriMix has an important added value, resulting in a significant reduction of tumor outgrowth and a marked increase in overall survival. "
07/01/2012 - "This case report indicates that administration of autologous TriMix-DC by the combined intradermal and intravenous route can mediate a durable objective tumor response accompanied by a broad T-cell response in a chemorefractory stage IV-M1c melanoma patient."
06/01/2011 - "Thirty-five American Joint Committee on Cancer stage III/IV melanoma patients received autologous TriMix-DC (4 administrations 2 weeks apart). "
02/01/2016 - "TriMix stimulated antitumor T-cell responses to spontaneously engulfed cancer antigens, including a neoepitope. "
07/01/2012 - "Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient."

03/01/2018 - "This article shares several lessons learned from the author's experience performing stability studies on Trimix injection, a sterile preparation for erectile dysfunction. "
09/01/2013 - "Physicochemical stability study of a new Trimix formulation for treatment of erectile dysfunction."
01/01/2021 - "Trimix is a widely prescribed penile injection for patients with erectile dysfunction and is only available as a compounded medication. "
05/01/2004 - "Long-term stability of trimix: a three-drug injection used to treat erectile dysfunction."
05/01/2001 - "A higher percentage of positive response in patients with erectile dysfunction was achieved with the trimix modality. "

04/01/2007 - "A rat model to study decompression sickness after a trimix dive."
06/01/2016 - "Inner-ear decompression sickness in nine trimix recreational divers."
04/01/2007 - "There is no specific recompression treatment for decompression sickness (DCS) resulting from trimix diving. "
04/01/2007 - "Decompression sickness in the rat following a dive on trimix: recompression therapy with oxygen vs. heliox and oxygen."
10/01/2012 - "Trimix SCUBA diving involves regulating mixtures of nitrogen, oxygen and helium in an attempt to overcome the risks of narcosis and decompression sickness during deep dives, but introduces other potential hazards such as hypoxia and oxygen toxicity convulsions. "

12/01/1982 - "Effect of compression rate on use of trimix to ameliorate HPNS in man to 686 m (2250 ft)."
06/01/1981 - "Control of HPNS in humans during rapid compression with trimix to 650 m (2131 ft)."
09/01/2003 - "Neuronal sensitivity to pressure, barosensitivity, is illustrated by high-pressure nervous syndrome, which manifests as increased central nervous system excitability when heliox or trimix is breathed at >15 atmospheres absolute (ATA). "
01/07/1984 - "The high pressure nervous syndrome (h.p.n.s.) was studied in man from clinical, electrophysiological and psychometric viewpoints during a variety of simulated dives to depths deeper than 300 m (between 300 and 610 m), which used different modes of compression and different gas mixtures (Heliox, Trimix). "
12/01/1979 - "As in man, in rats trimix increased the depth of the onset of HPNS tremors and myoclonic jerks in all six groups of rats. "

09/01/2014 - "Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula."
07/01/2012 - "This case report indicates that administration of autologous TriMix-DC by the combined intradermal and intravenous route can mediate a durable objective tumor response accompanied by a broad T-cell response in a chemorefractory stage IV-M1c melanoma patient."
06/01/2011 - "Thirty-five American Joint Committee on Cancer stage III/IV melanoma patients received autologous TriMix-DC (4 administrations 2 weeks apart). "
05/15/2009 - "TriMix DCs coelectroporated with tyrosinase are able to stimulate tyrosinase-specific CD8(+) T cells in vitro from the blood of nonvaccinated melanoma patients. "
07/01/2012 - "Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient."